- CRISPR gene-editing technologies, designed to enable precise and efficient modification of DNA, are becoming increasingly integral to therapeutic development, agriculture, and biomedical research due to their versatility, specificity, and transformative potential across multiple sectors
- The growth of the CRISPR gene-editing market is primarily driven by rising investments in genomic medicine, increasing research on rare and genetic disorders, and accelerating clinical trials aimed at developing gene therapies for conditions such as sickle cell disease, cancer, and inherited retinal disorders
- North America dominates the CRISPR gene-editing market with the largest revenue share of 38.5% in 2024, supported by a robust biotechnology ecosystem, strong academic research institutions, favourable regulatory frameworks, and substantial funding for genome-editing innovation and commercialization
- Asia-Pacific is expected to be the fastest growing region in the CRISPR gene-editing market, with an CAGR of 7.2% during the forecast period, propelled by expanding biotechnology capabilities, government-backed genomics initiatives, and a surge in R&D collaborations across countries such as China, Japan, and India
- The CRISPR or Cas9 technology segment dominates the CRISPR gene-editing market, accounting for 59.4% in 2024, owing to its widespread adoption, ease of use, and ongoing advancements that enhance precision, efficiency, and therapeutic safety across clinical and research applications
